244 related articles for article (PubMed ID: 30307119)
1. Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.
Paczesny S; Metzger J
Proteomics Clin Appl; 2019 Mar; 13(2):e1800145. PubMed ID: 30307119
[TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of graft-versus-host disease biomarkers.
Paczesny S
Blood; 2013 Jan; 121(4):585-94. PubMed ID: 23165480
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host disease biomarkers: omics and personalized medicine.
Paczesny S; Raiker N; Brooks S; Mumaw C
Int J Hematol; 2013 Sep; 98(3):275-92. PubMed ID: 23959582
[TBL] [Abstract][Full Text] [Related]
4. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
6. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.
Paczesny S
Br J Haematol; 2021 Mar; 192(6):951-967. PubMed ID: 32039480
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for posttransplantation outcomes.
Paczesny S
Blood; 2018 May; 131(20):2193-2204. PubMed ID: 29622549
[TBL] [Abstract][Full Text] [Related]
8. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
9. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Allogeneic HCT Outcomes.
Adom D; Rowan C; Adeniyan T; Yang J; Paczesny S
Front Immunol; 2020; 11():673. PubMed ID: 32373125
[TBL] [Abstract][Full Text] [Related]
11. Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.
Potter V; Moore J
Rev Recent Clin Trials; 2008 May; 3(2):130-8. PubMed ID: 18474024
[TBL] [Abstract][Full Text] [Related]
12. Proteomics for hematopoietic stem cell transplantation.
Weissinger EM; Basílio-Queirós D; Metzger J; Bieling LM; Ganser A
Expert Rev Proteomics; 2020 Mar; 17(3):201-206. PubMed ID: 32228239
[No Abstract] [Full Text] [Related]
13. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers in graft-versus-host disease: a new era?
Paczesny S; Levine JE; Braun TM; Ferrara JL
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):33-8. PubMed ID: 19147075
[TBL] [Abstract][Full Text] [Related]
16. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
17. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF
Leuk Res; 2017 Aug; 59():1-7. PubMed ID: 28527401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
